ES3041762T3 - High concentration anti-amyloid beta peptide protofibril antibody formulations and methods of use thereof - Google Patents

High concentration anti-amyloid beta peptide protofibril antibody formulations and methods of use thereof

Info

Publication number
ES3041762T3
ES3041762T3 ES21722538T ES21722538T ES3041762T3 ES 3041762 T3 ES3041762 T3 ES 3041762T3 ES 21722538 T ES21722538 T ES 21722538T ES 21722538 T ES21722538 T ES 21722538T ES 3041762 T3 ES3041762 T3 ES 3041762T3
Authority
ES
Spain
Prior art keywords
concentration
arginine
ban2401
pharmaceutical formulation
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21722538T
Other languages
English (en)
Spanish (es)
Inventor
Nobuo Yoshida
Naomi Sakuramoto
Takahisa Sakaguchi
Hirokazu Kito
Takahiro Ozawa
Anjali Joshi
Yung Yueh Hsu
Pierre Souillac
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75746958&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES3041762(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Application granted granted Critical
Publication of ES3041762T3 publication Critical patent/ES3041762T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
ES21722538T 2020-03-20 2021-03-19 High concentration anti-amyloid beta peptide protofibril antibody formulations and methods of use thereof Active ES3041762T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062992746P 2020-03-20 2020-03-20
US202063027263P 2020-05-19 2020-05-19
PCT/IB2021/000155 WO2021186245A1 (en) 2020-03-20 2021-03-19 HIGH CONCENTRATION ANTI-Aß PROTOFIBRIL ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF

Publications (1)

Publication Number Publication Date
ES3041762T3 true ES3041762T3 (en) 2025-11-14

Family

ID=75746958

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21722538T Active ES3041762T3 (en) 2020-03-20 2021-03-19 High concentration anti-amyloid beta peptide protofibril antibody formulations and methods of use thereof

Country Status (28)

Country Link
US (1) US20230183328A1 (cg-RX-API-DMAC7.html)
EP (2) EP4252777B1 (cg-RX-API-DMAC7.html)
JP (2) JP7689141B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220156534A (cg-RX-API-DMAC7.html)
CN (1) CN115315251A (cg-RX-API-DMAC7.html)
AU (1) AU2021238951A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018766A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174778A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022002517A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022012916A2 (cg-RX-API-DMAC7.html)
DK (1) DK4121007T3 (cg-RX-API-DMAC7.html)
ES (1) ES3041762T3 (cg-RX-API-DMAC7.html)
FI (1) FI4121007T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251087T1 (cg-RX-API-DMAC7.html)
HU (1) HUE072937T2 (cg-RX-API-DMAC7.html)
IL (2) IL326613A (cg-RX-API-DMAC7.html)
LT (1) LT4121007T (cg-RX-API-DMAC7.html)
MA (1) MA59082B1 (cg-RX-API-DMAC7.html)
MD (1) MD4121007T2 (cg-RX-API-DMAC7.html)
MX (1) MX2022011101A (cg-RX-API-DMAC7.html)
PH (1) PH12022552172A1 (cg-RX-API-DMAC7.html)
PL (1) PL4121007T3 (cg-RX-API-DMAC7.html)
PT (1) PT4121007T (cg-RX-API-DMAC7.html)
RS (1) RS67249B1 (cg-RX-API-DMAC7.html)
SI (1) SI4121007T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500350T1 (cg-RX-API-DMAC7.html)
TW (1) TWI923576B (cg-RX-API-DMAC7.html)
WO (1) WO2021186245A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021310926A1 (en) 2020-07-23 2023-03-23 Othair Prothena Limited Anti-abeta antibodies
JP2024525559A (ja) 2021-07-09 2024-07-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 アルツハイマー病治療用バイオマーカー
KR20240142535A (ko) 2022-02-02 2024-09-30 에자이 알앤드디 매니지먼트 가부시키가이샤 P-tau181 수준을 사용한 치료 방법
CN120202218A (zh) 2022-11-28 2025-06-24 卫材R&D管理有限公司 使用tau PET水平的治疗方法
IL324807A (en) 2023-06-09 2026-01-01 Eisai R&D Man Co Ltd Treatment methods using anti-Abeta protofibril antibody
WO2026015877A1 (en) 2024-07-12 2026-01-15 Eisai R&D Management Co., Ltd. Fluid biomarker

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
MD3672631T3 (ro) 2017-08-22 2023-09-30 Biogen Ma Inc Compoziții farmaceutice conținând anticorpi anti-beta amiloidici
WO2020023530A2 (en) * 2018-07-24 2020-01-30 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease

Also Published As

Publication number Publication date
SI4121007T1 (sl) 2025-10-30
DK4121007T3 (da) 2025-09-22
EP4121007B1 (en) 2025-07-02
IL326613A (en) 2026-04-01
MA59082B1 (fr) 2025-09-30
CL2022002517A1 (es) 2023-03-24
JP2023518066A (ja) 2023-04-27
SMT202500350T1 (it) 2025-11-10
IL295383A (en) 2022-10-01
JP7689141B2 (ja) 2025-06-05
EP4252777B1 (en) 2026-06-17
KR20220156534A (ko) 2022-11-25
CA3174778A1 (en) 2021-09-23
JP2025111516A (ja) 2025-07-30
EP4121007A1 (en) 2023-01-25
TWI923576B (zh) 2026-05-01
FI4121007T3 (fi) 2025-09-11
MX2022011101A (es) 2022-10-03
PT4121007T (pt) 2025-09-25
CO2022012916A2 (es) 2022-09-20
US20230183328A1 (en) 2023-06-15
EP4252777A2 (en) 2023-10-04
HRP20251087T1 (hr) 2025-11-07
TW202200201A (zh) 2022-01-01
CN115315251A (zh) 2022-11-08
LT4121007T (lt) 2025-09-25
IL295383B1 (en) 2026-04-01
IL295383B2 (en) 2026-08-01
HUE072937T2 (hu) 2025-12-28
EP4252777A9 (en) 2023-11-15
AU2021238951A1 (en) 2022-10-20
PL4121007T3 (pl) 2025-11-03
WO2021186245A1 (en) 2021-09-23
PH12022552172A1 (en) 2023-12-11
EP4252777A3 (en) 2024-01-24
MD4121007T2 (ro) 2025-11-30
BR112022018766A2 (pt) 2022-11-01
RS67249B1 (sr) 2025-10-31
CL2024003428A1 (es) 2025-04-11

Similar Documents

Publication Publication Date Title
TWI923576B (zh) 高濃度抗Aβ原纖維抗體配製物及其使用方法
ES2947488T3 (es) Formulación anti-IFNAR1 estable
JP5513380B2 (ja) 肝細胞増殖因子に対する特異的結合剤の組成物
TWI764097B (zh) 包含抗cd47抗體的製劑及其製備方法和用途
BR112012012080B1 (pt) Formulações de histidina-trealose do anticorpo t1h
CN104159612B (zh) Il-17抗体制剂
KR20160068946A (ko) 안정한 수성 항체 제제
BR112021007946A2 (pt) formulação de anticorpo
US12358981B2 (en) Anti-connexin antibody formulations
WO2017104778A1 (ja) 抗ヒトtslp受容体抗体含有医薬組成物
CN115803011A (zh) 用于高度浓缩蛋白质制剂的粘度降低赋形剂及其组合
CN114423414A (zh) 樟脑磺酸及其与阳离子赋形剂的组合作为高浓缩蛋白质制剂中的降粘剂
US20200299371A1 (en) Pharmaceutical composition comprising pegylated fab' fragment of anti-human ngf antibody
RU2846725C1 (ru) ВЫСОКОКОНЦЕНТРИРОВАННЫЕ СОСТАВЫ НА ОСНОВЕ АНТИТЕЛ К ПРОТОФИБРИЛЛАМ Аβ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
BR122025027938A2 (pt) FORMULAÇÕES DE ANTICORPO DE PROTOFIBRILA ANTI-Abeta DE CONCENTRAÇÃO ALTA E MÉTODOS DE USO DAS MESMAS
HK40102754A (en) High concentration anti-ass protofibril antibody formulations and methods of use thereof
HK40085437B (en) High concentration anti-amyloid beta peptide protofibril antibody formulations and methods of use thereof
HK40085437A (en) High concentration anti-amyloid beta peptide protofibril antibody formulations and methods of use thereof
KR20240038005A (ko) B7-h3 항체의 약학적 조성물 및 그것의 용도
HK40059591A (en) Preparations containing anti-cd47 antibody, and preparation method and use therefor
BR112018010211B1 (pt) Formulação farmacêutica aquosa de anticorpo, seu uso e frasco compreendendo a mesma
BR112020004902B1 (pt) Processo para formulação farmacêutica liofilizada de uma proteína terapêutica
HK1257781A1 (zh) 含抗-pd-l1抗体avelumab的水性药物制剂
BR112019007858B1 (pt) Composições farmacêuticas, métodos relacionados, kit, recipiente de dose única e uso